Format

Send to

Choose Destination
Arthritis Res Ther. 2018 Jul 11;20(1):139. doi: 10.1186/s13075-018-1631-y.

Methods for high-dimensonal analysis of cells dissociated from cyropreserved synovial tissue.

Author information

1
Hospital for Special Surgery, New York, NY, 10021, USA.
2
Weill Cornell Medical College, New York, NY, 10065, USA.
3
Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
4
Broad Institute of MIT and Harvard University, Cambridge, MA, 02142, USA.
5
University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USA.
6
University of Birmingham, Queen Elizabeth Hospital, B15 2WB, Birmingham, UK.
7
University of Rochester Medical Center, Rochester, NY, 14642, USA.
8
University of California San Diego School of Medicine, La Jolla, CA, 92093, USA.
9
Mile End Hospital, Barts Health NHS Trust, E1 1BB, London, UK.
10
Stanford University School of Medicine, Stanford, CA, 94305, USA.
11
University of Massachusetts Medical School, Worcester, MA, 01605, USA.
12
Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
13
Queen Mary University of London, E1 4NS, London, UK.
14
The Feinstein Institute for Medical Research, Manhasset, NY, 11030, USA.
15
University of Colorado of Denver School of Medicine, Aurora, CO, 80045, USA.
16
University of Rochester Medical Center, Rochester, NY, 14642, USA. jennifer_anolik@urmc.rochester.edu.

Abstract

BACKGROUND:

Detailed molecular analyses of cells from rheumatoid arthritis (RA) synovium hold promise in identifying cellular phenotypes that drive tissue pathology and joint damage. The Accelerating Medicines Partnership RA/SLE Network aims to deconstruct autoimmune pathology by examining cells within target tissues through multiple high-dimensional assays. Robust standardized protocols need to be developed before cellular phenotypes at a single cell level can be effectively compared across patient samples.

METHODS:

Multiple clinical sites collected cryopreserved synovial tissue fragments from arthroplasty and synovial biopsy in a 10% DMSO solution. Mechanical and enzymatic dissociation parameters were optimized for viable cell extraction and surface protein preservation for cell sorting and mass cytometry, as well as for reproducibility in RNA sequencing (RNA-seq). Cryopreserved synovial samples were collectively analyzed at a central processing site by a custom-designed and validated 35-marker mass cytometry panel. In parallel, each sample was flow sorted into fibroblast, T-cell, B-cell, and macrophage suspensions for bulk population RNA-seq and plate-based single-cell CEL-Seq2 RNA-seq.

RESULTS:

Upon dissociation, cryopreserved synovial tissue fragments yielded a high frequency of viable cells, comparable to samples undergoing immediate processing. Optimization of synovial tissue dissociation across six clinical collection sites with ~ 30 arthroplasty and ~ 20 biopsy samples yielded a consensus digestion protocol using 100 μg/ml of Liberase™ TL enzyme preparation. This protocol yielded immune and stromal cell lineages with preserved surface markers and minimized variability across replicate RNA-seq transcriptomes. Mass cytometry analysis of cells from cryopreserved synovium distinguished diverse fibroblast phenotypes, distinct populations of memory B cells and antibody-secreting cells, and multiple CD4+ and CD8+ T-cell activation states. Bulk RNA-seq of sorted cell populations demonstrated robust separation of synovial lymphocytes, fibroblasts, and macrophages. Single-cell RNA-seq produced transcriptomes of over 1000 genes/cell, including transcripts encoding characteristic lineage markers identified.

CONCLUSIONS:

We have established a robust protocol to acquire viable cells from cryopreserved synovial tissue with intact transcriptomes and cell surface phenotypes. A centralized pipeline to generate multiple high-dimensional analyses of synovial tissue samples collected across a collaborative network was developed. Integrated analysis of such datasets from large patient cohorts may help define molecular heterogeneity within RA pathology and identify new therapeutic targets and biomarkers.

KEYWORDS:

Accelerating Medicines Partnership; Arthroplasty; CyTOF; Mass cytometry; RNA sequencing; Rheumatoid arthritis; Synovial biopsy; Synovial tissue

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center